EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

BINEX Co. Ltd (053030) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of BINEX Co. Ltd KRW 1,844, price KRW 6,410, upside -71.2%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · KR · ISIN KR7053030003

BC Thin data Oct 2, 2026

BINEX Co. Ltd

053030 · KQ

Stretched ValuationStrong overvaluation with only moderate quality.

Solidly profitable · 10.7% net margin (TTM)
Low debt
Ranks above peers (5/8)
Quality 52/100
Mixed Growth (revenue 5y +4.8 %/yr in KRW)
Moderate moat 46/100
Fair value 1,844 KRW · Strongly overvalued (−71.2%)
Negative free cash flow
Thin data
Watch BINEX Co. Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

27,000 KRW 5,940 KRW Fair Value 1,844 KRW May 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.

How to read this chart

60‑month range 5,940 KRW – 27,000 KRW · fair‑value band 794.01 KRW – 2,895 KRW · the 6,410 KRW price screens above the 1,844 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 2, 2026.

Follow BINEX Co. in your weekly email

Every Wednesday you see whether BINEX Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

BINEX Co., Ltd. operates as a pharmaceutical company in South Korea.

Show more

BINEX Co., Ltd. operates as a pharmaceutical company in South Korea. It offers bisroot products; GI tract and antispasmodic, and antiulcer agents; NSAIDs; cardiovascular and urology products; hepatic protectors; ointments and creams; ophthalmic solutions; CNS agents; digestive products; constipation and blood circulation products; antibiotic and antifungal agents; cough and cold remedy products; vitamins and nutrients; antihistamine products; antivertigo products; and OTC products. BINEX Co., Ltd. has a co-development partnership with Genexine, Inc. to develop COVID-19 vaccine. The company was founded in 1957 and is based in Incheon, South Korea.

Stock analysis

BINEX Co. Ltd (053030) currently trades at 6,410 KRW, while our model-based Fair Value estimate is 1,844 KRW, 71.2% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 94/100, which puts the evidence level at low.

Scenario range: 794.01 KRW (bear) to 2,895 KRW (bull), the price of 6,410 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

BINEX Co. Ltd reported revenue of 168B KRW in FY2025 versus 134B KRW in FY2021, a compound +5.8%/yr. Reported net income was −3.2B KRW in FY2025.

Key figures

Market cap 204B KRW (≈ $152M) · P/S ratio 1.34 · Net margin −1.9% · Return on equity −1,423% · Return on assets (EBIT) −0.1% · Operating margin 14.7% · Revenue (TTM) 155B KRW · Revenue growth (YoY) +18.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).

What moves the price

The share trades about 61% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −37% fair-value upside, at −71%, 053030 screens richer than that median.

Fair Value models

Bear 794.01 KRW Fair Value 1,844 KRW Bull 2,895 KRW
Price 6,410 KRW · Upside -71.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EV/EBITDA 1,923 KRW 2,974 KRW 4,024 KRW 66
NCAV (Graham) 3,003 KRW 4,024 KRW 6,005 KRW 54
All 2 models by family
Multiples
EV/EBITDA 1,923 KRW 2,974 KRW 4,024 KRW 66
Asset-Based
NCAV (Graham) 3,003 KRW 4,024 KRW 6,005 KRW 54

Open the full fair value analysis →

Notify me when 053030 reaches fair value

Put 053030 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 52/100

Of which business quality 52 · Market factors (momentum, volatility) 20

Profitability 18
Margins and returns on capital today
Quality Growth 98
Are margins and returns improving?
Cashflow 33
Earnings quality: real cash, not paper profit
Fin. Strength 56
Balance sheet, leverage, solvency risk
Investment 76
Disciplined investing over empire-building
Low Volatility 49
Calm price path (market factor)
Momentum 11
Price trend over the last 3–12 months (market factor)
52W Momentum 2
Distance to the 52-week high (market factor)
Net Issuance 62
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 33/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+29.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.8%
Start year 2020 (pandemic). Over 10 years: +9.7% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
12.1% (2020) → −2.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

053030 screens overvalued: fair value 71% below the price. Compare with Caregen Co →

Compare BINEX Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 43 stocks

Beats the industry median on 5/8 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 52 · Below median
Fair Value upside −71.2% · Bottom 25%
Profitability
Return on assets 5.2% · Above median
Net margin (TTM) 10.7% · Top 25%
Operating margin (TTM) 14.7% · Top 25%
Growth and dividend
Revenue growth 18.3% · Above median
Balance sheet
Debt / equity 0.30× · Highest 25%

Valuation Multiplesvs Pharmaceuticals median · lower = cheaper

EV/EBITDA 1.3× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 23
FUTURE (revenue growth)92 · sector 55
PAST (return on equity)0 · sector 10
HEALTH (low debt)85 · sector 98
DIVIDEND (yield)0 · sector 24

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Caregen Co 214370 40,850 KRW 5,414 KRW −87%
ST Pharm Co 237690 91,700 KRW 50,110 KRW −45%
Oscotec Inc 039200 35,650 KRW 21,262 KRW −40%
DongKook Pharmaceutical Co 086450 22,150 KRW 28,372 KRW +28%
SHUKRAPHAR SHUKRAPHAR ₹61.84 ₹8.38 −86%
Huons Global Co 084110 22,950 KRW 46,562 KRW +103%
Kolon Life Science Inc 102940 14,800 KRW 37,129 KRW +151%
VIKRAMTH VIKRAMTH ₹405.90 ₹444.16 +9%
JW Shinyak Corporation 067290 2,990 KRW 1,326 KRW −56%
EURO EURO 1.20 PHP 0.7600 PHP −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

BINEX Co. Ltd · Fair Value
1,844 KRW −71%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "BINEX Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/053030

Frequently asked questions

Is BINEX Co. Ltd (053030) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of 1,844 KRW versus a price of 6,410 KRW, about −71% upside (overvalued).
What is the fair value of 053030?
Our model-based fair value for BINEX Co. Ltd is 1,844 KRW (as of Oct 2, 2026), built from audited fundamentals. The current price: 6,410 KRW.
What is the quality score of 053030?
BINEX Co. Ltd has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BINEX Co. Ltd (053030)?
Our model-based price target is the fair value of 1,844 KRW (as of Oct 2, 2026) from 2 valuation models. Cautious scenario 794.01 KRW, optimistic scenario 2,895 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the BINEX Co. Ltd stock forecast for 2026?
Our models put fair value at 1,844 KRW, about −71% upside versus a price of 6,410 KRW (overvalued). Cautious scenario 794.01 KRW, optimistic scenario 2,895 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of BINEX Co. Ltd (053030)?
BINEX Co. Ltd reported trailing-twelve-month revenue of about 155B KRW (latest available figure, as of Oct 2, 2026).
What is the intrinsic value of BINEX Co. Ltd (053030)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BINEX Co. Ltd it is 1,844 KRW per share (as of Oct 2, 2026), against a price of 6,410 KRW. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is BINEX Co. Ltd stock overvalued or undervalued in 2026?
As of Oct 2, 2026, 053030 trades above its calculated fair value: price 6,410 KRW, fair value 1,844 KRW, a gap of about −71% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 053030?
No. The price is what the market pays today (6,410 KRW); the fair value is what the company's own numbers justify (1,844 KRW). For BINEX Co. Ltd the two are 4,566 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is BINEX Co. Ltd worth?
The market values BINEX Co. Ltd at about 204B KRW (market capitalisation, as of Oct 2, 2026). Per share that is 6,410 KRW; our models calculate a fair value of 1,844 KRW per share.
What do the bullish and bearish scenarios say about 053030?
Our models span a range for BINEX Co. Ltd: cautious scenario 794.01 KRW, base 1,844 KRW, optimistic 2,895 KRW per share (as of Oct 2, 2026, price 6,410 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of BINEX Co. Ltd (053030)?
Balance-sheet figures for BINEX Co. Ltd (as of Oct 2, 2026): debt of 0.30 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is 053030 from its 52-week high?
BINEX Co. Ltd trades at 6,410 KRW, about 61% below its 52-week high of 16,400 KRW and 8% above the low of 5,940 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 1,844 KRW is for.
Which stocks are comparable to BINEX Co. Ltd?
From the same area (Healthcare) we also value Caregen Co, ST Pharm Co, Oscotec Inc, DongKook Pharmaceutical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BINEX Co. Ltd stock attractive at the current price?
The data as of Oct 2, 2026: price 6,410 KRW, calculated fair value 1,844 KRW (−71%), Quality Score 52/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 053030 calculated?
We run BINEX Co. Ltd through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1,844 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. BINEX Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BINEX Co. Ltd (053030)?
The closing price on Oct 2, 2026 was 6,410 KRW. Our model-based fair value is 1,844 KRW, about −71% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BINEX Co. Ltd right now?
The price sits above even our optimistic bull case (2,895 KRW). The favourable scenario is already priced in. The model range is unusually wide (794.01 KRW to 2,895 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of BINEX Co. Ltd

How large is the market capitalisation of BINEX Co. Ltd (053030)?
The market capitalisation of BINEX Co. Ltd is 204B KRW (≈ $152M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BINEX Co. Ltd (053030)?
The price-to-sales ratio of BINEX Co. Ltd is 1.34 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of BINEX Co. Ltd (053030)?
The net margin of BINEX Co. Ltd is −1.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BINEX Co. Ltd (053030)?
The return on equity (ROE) of BINEX Co. Ltd is −1,423% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BINEX Co. Ltd (053030)?
On an EBIT basis the return on assets of BINEX Co. Ltd is −0.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BINEX Co. Ltd (053030)?
The operating margin of BINEX Co. Ltd is 14.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BINEX Co. Ltd (053030)?
Revenue at BINEX Co. Ltd is growing +18.3% versus a year earlier (3y avg +2.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at BINEX Co. Ltd (053030)?
Earnings per share at BINEX Co. Ltd are growing +126% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does BINEX Co. Ltd (053030) generate?
The free cash flow of BINEX Co. Ltd is −46.5B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does BINEX Co. Ltd (053030) carry?
The net debt of BINEX Co. Ltd is 73.5B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch BINEX Co. Ltd in the live analysis

One click puts BINEX Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.